Amarin Corporation

$AMRN shareholders: Our Q2 2024 financial results will be announced on July 31st at 8 am ET. We would like to encourage our shareholders to submit questions in advance to be addressed during the conference call. Please submit here: https://lnkd.in/e6CZGdJ4

Today, Amarin congratulates its partner Eddingpharm on the expanded indication regulatory approval for VASCEPA® (icosapent ethyl) in Mainland China. This milestone is a major step forward to help ensure that the unique benefits of VASCEPA are accessible to patients throughout the world. Read our press release here: https://lnkd.in/ex6sDbmm

Amarin Corporation, a dedicated advocate for cardiovascular health, stands in full support of HealthyWomen's Citizen Petition. We urge the FDA to review this issue and take action. Read our public comment here: https://lnkd.in/dDHJTM7M. Together, let's make a difference! Help address this patient care issue by providing public comment on this issue here: https://bit.ly/3KDoKef #CVHealth #PublicHealth #FDAActionNeeded

Congratulations to our colleagues at #AmarinEspaña, who have been awarded by La Razón at the 2024 #PremiosATuSalud ceremony in Madrid, celebrated yesterday, with the “Best Cardiovascular Risk Prevention Product Award.” "We are extremely proud with this recognition, which gives us the opportunity to raise awareness about the importance of cardiovascular health and the need for innovative approaches to ensure better outcomes for patients and an efficient use of healthcare resources." – Salvador López Orland, General Manager Amarin Spain and Portugal. Learn more: https://lnkd.in/d9ySb-pn

Today Amarin’s Board of Directors announced a CEO transition, with Aaron Berg being named Amarin’s new President & CEO. Read more about the announcement and Aaron’s experience here: https://bit.ly/4bLCpf7

$AMRN shareholders: We’re one week out from our Q1 2024 earnings call, happening May 1st at 8 am ET. We encourage our shareholders to submit questions in advance to be addressed during the conference call. Please submit questions here: https://lnkd.in/exWu2A9m

Today we announced the shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting, including the previously announced intent to pursue a share repurchase program of up to $50 million. Read more about the meeting results: https://lnkd.in/eVA_muA4

Calling all $AMRN shareholders: Our Q1 2024 financial result will be announced May, 1st at 8 am ET. We encourage our shareholders to submit questions in advance to be addressed during the conference call. Please submit here: https://lnkd.in/exWu2A9m

Last weekend we met with 120 leading cardiologists from Spain and the world at our "Inflexion" event in Madrid, where we discussed the inflection point that is being experienced in the approach to #CardiovascularRisk. Both panelists and audience highlighted the growing recognition of the scientific evidence behind it and its positive impact on the lives of patients.   We are very proud of our contribution to Spain in this area. We have achieved this thanks to the support of those who accompanied us at the event and the medical community in general, which recognizes the need and opportunity that the adequate management of cardiovascular risk represents to improve the health and well-being of patients. Video highlights: https://lnkd.in/e2QBiYtw   #CVD #Cardiovascular

$AMRN shareholders: The announcement of our fourth quarter and full-year 2023 financial results is a week away on February 29th at 8 am ET. We are still accepting questions and encourage shareholders to submit them in advance for addressing during the conference call. Please submit your questions here: https://bit.ly/3w0qVEv by February 27th, 8 am ET.